uniQure develops gene therapies for rare and serious diseases, including Huntington's disease and Fabry disease. It last closed at $19.35 on Nov 20, down 4.35% on the day. The next earnings report for QURE is expected around Mon, Mar 1, 2027. For the quarter ended Sep 2026, QURE reported EPS of -$0.88 on revenue of $5.2M, with revenue up 40.4% from a year ago. Over its last 8 reports the stock moved an average of 8.8% the session after earnings. Over the last 12 months QURE insiders bought $0 of stock on the open market and sold $20.2M, according to SEC Form 4 filings.
AI Auto Pilots
Is QURE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold QURE.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on QUREStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
QURE · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 17% below its 20 day and 40% below its 50 day average. It is 53% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the Pivot S1 at $18.37, and the nearest resistance the Pivot at $19.98.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 9.4%/day
Key levels
$51.7252 week high+167.3%
$35.68100 day average+84.4%
$29.52200 day average+52.6%
$27.0550 day average+39.8%
$26.20Swing high (Nov 12)+35.4%
$22.7320 day average+17.5%
$20.97Pivot R1+8.4%
$19.98Pivot+3.3%
$19.35Last close
$18.37Pivot S1−5.1%
$8.7352 week low−54.9%
Indicators
RSI (14)
32.66
Weak, oversold below 30
Neutral
MACD
-1.65
Below its signal line
Bearish
Stochastic
3.3
Near the bottom of its range
Oversold
ADX (14)
22.2
Weak trend
Williams %R
-95.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-140.6
Oversold below −100, overbought above 100
Oversold
Rate of change
−10.8%
Change over 10 sessions
Bearish
ATR (14)
$1.82
Typical daily range, 9.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, nearing oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 29.6%/day
Key levels
$51.7252 week high+167.3%
$35.68100 day average+84.4%
$29.52200 day average+52.6%
$27.0550 day average+39.8%
$26.20Swing high (Nov 12)+35.4%
$22.7320 day average+17.5%
$20.97Pivot R1+8.4%
$19.98Pivot+3.3%
$19.35Last close
$18.37Pivot S1−5.1%
$8.7352 week low−54.9%
Indicators
RSI (14)
36.19
Weak, oversold below 30
Neutral
MACD
-3.08
Below its signal line
Bearish
Stochastic
5.5
Near the bottom of its range
Oversold
ADX (14)
25.5
Trending down
Williams %R
-98.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-101.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−56.5%
Change over 10 sessions
Bearish
ATR (14)
$5.73
Typical daily range, 29.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for QURE
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how QURE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow QURE usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for QUREHow many large options trades hit QURE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in QURE in the last 90 days.
From SEC Form 4 filings by QURE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether QURE is in one of them and how their past QURE trades turned out.
uniQure is a gene therapy company based in Amsterdam. It develops treatments meant to be given as a single dose to patients with rare and other serious diseases. Its clinical programs target Huntington's disease, temporal lobe epilepsy, Fabry disease, and a form of amyotrophic lateral sclerosis linked to SOD1 gene mutations. These candidates are still in clinical development and have not yet been approved for sale.